Select Scientific Publications

Apnimed is committed to advancing research in sleep-related breathing diseases. Below is a selection of key publications and presentations about obstructive sleep apnea (OSA) and our work.

Quick jump:

Obstructive Sleep Apnea (OSA)

Every night, nearly 1 billion people with OSA worldwide stop breathing, exposing them to serious, long-term health risks.¹

Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Benjafield AV et al. Lancet Respir Med. 2019;7(8):687-698.

The hypoxic burden of sleep apnoea predicts cardiovascular disease-related mortality: the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study. Azarbarzin A et al. Eur Heart J. 2019;40(14):1149-1157.

Targeting endotypic traits with medications for the pharmacological treatment of obstructive sleep apnea. A review of the current literature. Taranto-Montemurro L, et al. J Clin Med. 2019;8(11)1846.

Upper airway muscles: influence on obstructive sleep apnoea pathophysiology and pharmacological and technical treatment options. Perger E, Taranto-Montemurro L. Curr Opin Pulm Med. 2021;27(6):505-513.

Hypoxic burden of sleep apnea: measurement and associations with outcomes. Azarbarzin A. May 23, 2023.

The impact of fatigue and sleepiness on patients with OSA: a closer look with patient reported outcome measures. Emsellem H, et al. SLEEP. 2024;47(Suppl 1):A200.

Prevalence of obesity in obstructive sleep apnea within a large community-based cohort of middled-aged/older adults. Esmaeili N, et al. SLEEP. 2024;47(Suppl 1): A372.

AD109

AD109 is an investigational oral therapy designed to improve oxygenation during sleep by directly addressing the underlying neuromuscular cause of upper airway collapse in people with OSA.

Combination of atomoxetine with the novel antimuscarinic aroxybutynin improves mild to moderate OSA. Rosenberg R, Abaluck B, Thein S. J Clin Sleep Med. 2022;18(12):2837-2844.

The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): a randomized controlled trial. Schweitzer PK, et al. Am J Respir Crit Care Med. 2023;208(12):1316-1327.

Obesity and self-reported symptom https://erj.ersjournals.com/ content/62/suppl_67/ PA3594s as determinants of responses to atomoxetine and aroxybutynin for sleep apnea. Messineo L, et al. Eur Resp J. 2023;62:PA3594.

Development of a combination of noradrenergic and antimuscarinic drugs for the treatment of obstructive sleep apnea: Challenges and progress. Taranto-Montemurro L, Pho H, White DP. Front Sleep. 2023. 2:1148282.

Aroxybutynin and Atomoxetine (AD109) for the Treatment of OSA: Rationale and Design of the LunAIRo Phase 3 Randomized, Controlled Clinical Trial. Patel, SR, Taranto Montemurro L, Farkas R, and for the LUNAIRO investigators. Am J Respir Crit Care Med 2024;209:A4551.

Aroxybutynin and atomoxetine for the treatment of OSA: rationale and design of the SynAIRgy phase 3 RCT. Strollo P, Taranto-Montemurro L. SLEEP. 2024;47(Suppl 1):A233-A234.

Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Benjafield AV et al. Lancet Respir Med. 2019;7(8):687-698.

Disclaimer: On this page, you may select links to key publications from peer-reviewed journals as well as to materials presented at scientific conferences relating either to research studies involving Apnimed’s product candidates or the science guiding our discovery, research, and development efforts. The safety and efficacy of any investigational product discussed in these materials has yet to be determined. Note that certain of these materials were authored by unaffiliated third parties and do not represent Apnimed’s views. The content of each work is the property of the respective copyright holder and may not be further distributed without their express permission. The information in these materials may not be current or comprehensive, and Apnimed undertakes no obligation to correct or update such information.